Product Use Citations
-
Liu Y, et al. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function
FASEB J. 2015, 29(12):4829-39.
Thalidomide purchased from Selleck.
-
Kim EY, et al. Syndecan-4 ectodomain evokes mobilization of podocyte TRPC6 channels and their associated pathways: An essential role for integrin signaling
Biochim Biophys Acta. 2015, 1853(10 Pt A):2610-20.
Cilengitide trifluoroacetate purchased from Selleck.
-
Zhou Y, et al. TSC2/mTORC1 signaling controls Paneth and goblet cell differentiation in the intestinal epithelium.
Cell Death Dis. 2015, 6:e1631.
Dibenzazepine (YO-01027) purchased from Selleck.
-
Wagner AH, et al. JAK1/STAT3 activation directly inhibits IL-12 production in dendritic cells by preventing CDK9/P-TEFb recruitment to the p35 promoter
Biochem Pharmacol. 2015, 10.1016/j.bcp.2015.04.019.
Ruxolitinib (INCB018424) purchased from Selleck.
-
Cheng H, et al. Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells.
Oncotarget. 2016, 7(20):28976-88.
Verteporfin purchased from Selleck.
-
Liu Z, et al. EGFRvIII/integrin β3 interaction in hypoxic and vitronectinenriching microenvironment promote GBM progression and metastasis.
Oncotarget. 2016, 7(4):4680-94.
Cilengitide trifluoroacetate purchased from Selleck.
-
Lin J, et al. Osteopontin (OPN/SPP1) isoforms collectively enhance tumor cell invasion and dissemination in esophageal adenocarcinoma.
Oncotarget. 2015, 6(26):22239-57.
Cilengitide trifluoroacetate purchased from Selleck.
-
Geng L, et al. GLI1 inhibitor GANT61 exhibits antitumor efficacy in T-cell lymphoma cells through down-regulation of p-STAT3 and SOCS3.
Oncotarget. 2016, 10.18632/oncotarget.9792.
GANT61 purchased from Selleck.
-
Ganguly S, et al. Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia.
Oncotarget. 2015, 6(31):31767-79.
Triptolide (PG490) , C646 purchased from Selleck.
-
Hirano T, et al. In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.
Oncotarget. 2015, 6(36):38789-803.
Rociletinib (CO-1686, AVL-301) purchased from Selleck.
-Oncotarget-20170209.gif)
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- 172
- 173
- 174
AllPage:
Page:
